About Edulis Therapeutics

Develops a bioresorbable endoscopic drug delivery system that implants a thin, polymer-based device to release small molecule medications directly in the gastrointestinal tract. This approach improves treatment for chronic conditions like inflammatory bowel disease by providing sustained, maintenance-free therapy for up to 12 months, reducing systemic side effects and lowering long-term patient costs. The system is designed for easy adoption by GI clinicians, requiring minimal training and offering a safer alternative to oral and surgical treatments.

```xml <problem> Current treatments for chronic gastrointestinal conditions, such as inflammatory bowel disease (IBD), often rely on oral medications or surgical interventions, which can lead to systemic side effects, reduced bioavailability, and high long-term costs for patients. Sustained drug delivery to the GI tract remains a challenge, requiring frequent dosing and potentially invasive procedures. </problem> <solution> Edulis Therapeutics is developing a bioresorbable endoscopic drug delivery system designed to provide localized and sustained release of small molecule medications directly within the gastrointestinal tract. The system utilizes a thin, polymer-based implant that is inserted endoscopically and releases medication at a controlled rate for up to 12 months. This approach aims to improve treatment efficacy, reduce systemic exposure to drugs, and lower overall patient costs by providing maintenance-free therapy. The implant is designed for ease of use by gastroenterologists, requiring minimal training and offering a less invasive alternative to traditional treatments. </solution> <features> - Bioresorbable polymer matrix for controlled drug release in the GI tract - Endoscopically delivered implant thinner than a grain of rice - Sustained therapeutic management for up to 12 months from a single implant - Higher bioavailability compared to oral formulations, reducing systemic side effects - Custom-made insertion tool accessible to all GI clinicians with minimal training - Capacity to extend the therapeutic window and enhance the bioavailability of existing small molecule medications </features> <target_audience> The primary target audience includes gastroenterologists and other clinicians treating patients with chronic gastrointestinal conditions such as inflammatory bowel disease (IBD). </target_audience> ```

What does Edulis Therapeutics do?

Where is Edulis Therapeutics located?

Edulis Therapeutics is based in Pittsburgh, United States.

When was Edulis Therapeutics founded?

Edulis Therapeutics was founded in 2022.

How much funding has Edulis Therapeutics raised?

Edulis Therapeutics has raised 830000.

Location

Pittsburgh, United States

Founded

2022

Funding

830000

Employees

3 employees

Looking for specific startups?

Try our free semantic startup search

Edulis Therapeutics

Score: 82/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

edulis.xyz 100+

Crunchbase

Founded 2022 – Pittsburgh, United States

Funding

Estimated Funding

$830K+

Team (<5)

No team information available. Click "Fetch founders" to run a focused founder search.

Company Description

Problem

Current treatments for chronic gastrointestinal conditions, such as inflammatory bowel disease (IBD), often rely on oral medications or surgical interventions, which can lead to systemic side effects, reduced bioavailability, and high long-term costs for patients. Sustained drug delivery to the GI tract remains a challenge, requiring frequent dosing and potentially invasive procedures.

Solution

Edulis Therapeutics is developing a bioresorbable endoscopic drug delivery system designed to provide localized and sustained release of small molecule medications directly within the gastrointestinal tract. The system utilizes a thin, polymer-based implant that is inserted endoscopically and releases medication at a controlled rate for up to 12 months. This approach aims to improve treatment efficacy, reduce systemic exposure to drugs, and lower overall patient costs by providing maintenance-free therapy. The implant is designed for ease of use by gastroenterologists, requiring minimal training and offering a less invasive alternative to traditional treatments.

Features

Bioresorbable polymer matrix for controlled drug release in the GI tract

Endoscopically delivered implant thinner than a grain of rice

Sustained therapeutic management for up to 12 months from a single implant

Higher bioavailability compared to oral formulations, reducing systemic side effects

Custom-made insertion tool accessible to all GI clinicians with minimal training

Capacity to extend the therapeutic window and enhance the bioavailability of existing small molecule medications

Target Audience

The primary target audience includes gastroenterologists and other clinicians treating patients with chronic gastrointestinal conditions such as inflammatory bowel disease (IBD).